Printer Friendly
The Free Library
19,111,409 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Rodman & Renshaw, LLC Announces Investment Opinion on Pharmacyclics.


NEW YORK New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
 -- Rodman & Renshaw, LLC (Logical Link Control) See "LANs" under data link protocol.

LLC - Logical Link Control
 

--Rodman & Renshaw, LLC Initiates Coverage of Pharmacyclics With A Market Outperform market outperform

An analyst recommendation that a stock is expected to outperform the overall market.
 Rating

--Analyst Sets 12 Month Target Price of $22.00

Rodman & Renshaw, LLC initiated research coverage of Pharmacyclics (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: PCYC PCYC Police Citizens Youth Club
PCYC Palmer's Cove Yacht Club (Salem, Massachusetts)
PCYC Perche Creek Yacht Club (Columbia, Missouri) 
 - News) with a Market Outperform Rating and a 12-month price target $22.00. Matthew N. Murray, Senior Biotechnology Analyst, issued the report.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a privately held, full-service investment bank committed to fostering the long-term success of growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. More information is available at www.rodmanandrenshaw.com

None of the research analysts or the research analyst's household has a financial interest in the securities of Pharmacyclics (including, without limitation, any option, right, warrant, future, long or short position).

As of September 30, 2005, neither Rodman & Renshaw, LLC nor its affiliates beneficially own 1% or more of any class of common equity securities of Pharmacyclics

Neither the research analyst nor Rodman & Renshaw, LLC has any material conflict of interest with Pharmacyclics, of which the research analyst knows or has reason to know at the time of publication of this research report.

Rodman & Renshaw, LLC or its affiliates did not receive compensation from Pharmacyclics for investment banking services within the last twelve months and Rodman & Renshaw, LLC intends to seek compensation from Pharmacyclics for investment banking services within three months, following publication of the research report.

Neither the research analyst nor any member of the research analyst's household nor Rodman & Renshaw, LLC serves as an officer, director or advisory board member of Pharmacyclics

Rodman & Renshaw, LLC makes a market in Pharmacyclics securities as of the date of this research report.

The above information is not intended to be used as a primary basis of investment decisions. It is not a representation by Rodman & Renshaw, LLC or an offer or the solicitation solicitation

In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual
 of an offer to buy any security. Before investing in Pharmacyclics, you should carefully consider your risk tolerance Risk Tolerance

The degree of uncertainty that an investor can handle in regards to a negative change in the value of their portfolio.

Notes:
An investor's risk tolerance varies according to age, income requirements, financial goals, etc.
 and financial objectives.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 8, 2005
Words:334
Previous Article:Air Liquide Industrial U.S. LP Announces Price Increases.
Next Article:Turner Construction and the National Building Museum Close ''Green'' Conference with Continued Commitment to Green Building Industry; 2005 Green...



Related Articles
Rodman & Renshaw, LLC Announces Investment Opinion on Halozyme Therapeutics, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion on Javelin Pharmaceuticals, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion on Myriad Genetics, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Palatin Technologies With A Market Outperform Rating;...
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Vivus, Inc. With A Market Outperform Rating; Analyst...
Rodman & Renshaw, LLC Announces Investment Opinion on NMT Medical, Inc.; Rodman & Renshaw, LLC Initiates Coverage of NMT Medical, Inc. With A Market...
Rodman & Renshaw, LLC Announces Investment Opinion on Hana Biosciences, Inc.; Rodman & Renshaw, LLC Initiates Coverage of Hana Biosciences, Inc. With...
Rodman & Renshaw, LLC Announces Investment Opinion on Novavax, Inc.; Rodman & Renshaw, LLC Initiates Coverage of Novavax, Inc. With A Market...
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Avalon Pharmaceuticals, Inc. With A Market Outperform...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles